María Gión

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 237 citations · Full text

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Nadia Harbeck, Eva Ciruelos, Guy Jérusalem et al. · Nature Medicine · 2024 · 141 citations · Full text

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)

Carmine Pinto, Francesca Di Fabio, Evaristo Maiello et al. · Annals of Oncology · 2011 · 59 citations

Surgical Oncology, Health Sciences, Radiation Therapy +10

Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto et al. · JAMA · 2023 · 49 citations · Full text